ENS 57657: Difference between revisions

From kanterella
Jump to navigation Jump to search
(StriderTol Bot insert)
 
(StriderTol Bot change)
 
Line 25: Line 25:
The following additional information was obtained from the licensee in accordance with Headquarters Operations Officers Report Guidance:
The following additional information was obtained from the licensee in accordance with Headquarters Operations Officers Report Guidance:
Discussions with the licensee revealed that the report is being submitted pursuant to 10 CFR 20.2202(b)(1)(i) for an individual potentially exceeding a total effective dose equivalent of 5 rem within 24 hours due to a loss of control of licensed material. Additionally, a 30-day report will be submitted pursuant to 10 CFR 20.2203(a)(2)(i) for an adult receiving an annual occupational total effective dose equivalent in excess of 5 rem.
Discussions with the licensee revealed that the report is being submitted pursuant to 10 CFR 20.2202(b)(1)(i) for an individual potentially exceeding a total effective dose equivalent of 5 rem within 24 hours due to a loss of control of licensed material. Additionally, a 30-day report will be submitted pursuant to 10 CFR 20.2203(a)(2)(i) for an adult receiving an annual occupational total effective dose equivalent in excess of 5 rem.
| URL = https://www.nrc.gov/reading-rm/doc-collections/event-status/event/2025/20250417en.html#en57657
| URL = https://www.nrc.gov/reading-rm/doc-collections/event-status/event/2025/20250418en.html#en57657
}}
}}


{{ENS-Nav}}
{{ENS-Nav}}

Latest revision as of 06:20, 18 April 2025

ENS 57657 +/-
Where
Curium Pharma
Noblesville, Indiana (NRC Region 3)
License number: 13-35179-02
Organization: Curium Pharma
Reporting
10 CFR 20.2202(b)(1)
Time - Person (Reporting Time:+14.6 h0.608 days <br />0.0869 weeks <br />0.02 months <br />)
Opened: Matthew Trusner
09:54 Apr 9, 2025
NRC Officer: Tenisha Meadows
Last Updated: Apr 9, 2025
57657 - NRC Website